With litigation and a fast-approaching election complicating the picture, clinical labs and IVD manufacturers alike are still sizing up potential outcomes of the US Food and Drug Administration’s final rule on LDTs, speakers said during a 21 October webinar sponsored by 360Dx and ZeptoMetrix.
For labs, a key concern remains the potential business effects of the increased regulatory burden.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?